Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Du, Yong (The Royal Marsden NHS Foundation Trust)
Carrió, Ignasi (Institut d'Investigació Biomèdica Sant Pau)
De Vincentis, Giuseppe (Policlinico Umberto I University Hospital Rome)
Fanti, Stefano (University Hospital Bologna)
Ilhan, Harun (Ludwig-Maximilians-University Hospital)
Mommsen, Caroline (Praxis für diagnostische und therapeutische Nuklearmedizin Berlin)
Nitzsche, Egbert (Cantonal Hospital Aarau)
Sundram, Francis (University Hospital Southampton NHS Foundation Trust (Regne Unit))
Vogel, Wouter (The Netherlands Cancer Institute (Amsterdam, Països Baixos))
Oyen, Wim (The Institute of Cancer Research)
Lewington, Val (Guy's and St Thomas' NHS Foundation Trust)
Universitat Autònoma de Barcelona

Fecha:	2017
Resumen:	Radium Ra 223 dichloride (radium-223, Xofigo®) is the first targeted alpha therapy for patients with castration-resistant prostate cancer and symptomatic bone metastases. Radium-223 provides a new treatment option for this setting, but also necessitates a new treatment management approach. We provide straightforward and practical recommendations for European nuclear medicine centres to optimize radium-223 service provision. An independent research consultancy agency observed radium-223 procedures and conducted interviews with all key staff members involved in radium-223 treatment delivery in 11 nuclear medicine centres across six countries (Germany, Italy, the Netherlands, Spain, Switzerland and the UK) experienced in administering radium-223. The findings were collated and discussed at a meeting of experts from these centres, during which key consensus recommendations were defined. The recommendations cover centre organization and preparation; patient referral; radium-223 ordering, preparation and disposal; radium-223 treatment delivery/administration; and patient experience. Guidance includes structured coordination and communication within centres and multidisciplinary teams, focusing on sharing best practice to provide high-quality, patient-centred care throughout the treatment pathway. These expert recommendations are intended to complement existing management guidelines. Sharing best practice and experience will help nuclear medicine centres to optimize radium-223 service provision and improve patient care.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Bone metastases ; Castration-resistant prostate cancer ; Nuclear medicine ; Ra-223 ; Radium dichloride ; Targeted alpha therapy
Publicado en:	European Journal of Nuclear Medicine and Molecular Imaging, Vol. 44 Núm. 10 (january 2017) , p. 1671-1678, ISSN 1619-7089

DOI: 10.1007/s00259-017-3756-7
PMID: 28631036

8 p, 547.4 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados